Holen Sie sich die Stockscreener-App
48.78
0.35%
0.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$48.61
Offen:
$48.28
24-Stunden-Volumen:
1.84M
Relative Volume:
0.80
Marktkapitalisierung:
$7.65B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
51.89
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
+0.18%
1M Leistung:
-3.39%
6M Leistung:
-35.00%
1J Leistung:
-37.38%
1-Tages-Spanne:
$47.54
$49.53
1-Wochen-Bereich:
$47.23
$49.53
52-Wochen-Spanne:
$46.01
$83.62
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
48.78 | 7.63B | 1.17B | 150.71M | 245.03M | 0.94 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne at William Blair Growth Stock: Strategic Insights and Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1 - Yahoo Finance
Wells Fargo Begins Coverage of Bio-Techne (TECH) Stock, Gives PT of $59 - Insider Monkey
Wells Fargo starts Bio-Techne with Overweight, $59 target - Investing.com Australia
Bio-Techne stock price target cut to $65 by Argus - Investing.com South Africa
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overwei - GuruFocus
Wells Fargo starts Bio-Techne with Overweight, $59 target By Investing.com - Investing.com Canada
Demystifying Bio-Techne: Insights From 7 Analyst Reviews - Benzinga
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overweight Rating | TECH Stock News - GuruFocus
Argus Adjusts Price Target on Bio-Techne to $65 From $90 - marketscreener.com
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target - marketscreener.com
Bio-Techne Corporation (TECH): A Bull Case Theory - Insider Monkey
Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment! - Smartkarma
Is Bio-Techne Stock The Right Pick For Your Portfolio Now? - Barchart.com
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Nasdaq
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne to Present at Investor Conferences - Yahoo Finance
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Do Wall Street Analysts Like Bio-Techne Stock? - MSN
(TECH) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bio-Techne (NASDAQ:TECH) Rating Increased to Buy at StockNews.com - Defense World
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and Affiliated Managers Group - Nasdaq
Wednesday Sector Laggards: Healthcare, Materials - Nasdaq
What Makes Bio-Techne Corporation (TECH) a Compelling Addition? - Insider Monkey
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) - Quantisnow
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges By Investing.com - Investing.com Nigeria
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - The Malaysian Reserve
Bio-Techne to Showcase Next-Generation Solutions for Gene and Ce - GuruFocus
UBS Group Cuts Bio-Techne (NASDAQ:TECH) Price Target to $70.00 - Defense World
When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com
StockNews.com Downgrades Bio-Techne (NASDAQ:TECH) to Hold - Defense World
Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Sto - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus
Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):